Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year High – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares reached a new 52-week high during trading on Friday . The company traded as high as $96.78 and last traded at $95.35, with a volume of 5603827 shares changing hands. The stock had previously closed at $91.57.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price for the company. Wedbush upped their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Robert W. Baird lifted their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Price Performance

The stock has a 50 day moving average of $86.45 and a 200 day moving average of $68.02. The firm has a market cap of $5.21 billion, a P/E ratio of -23.09 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the transaction, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 179,121 shares of company stock worth $15,059,454 over the last ninety days. Insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. State Street Corp increased its stake in Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Braidwell LP purchased a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $32,859,000. Finally, Polar Capital Holdings Plc bought a new stake in Dianthus Therapeutics in the third quarter valued at approximately $29,434,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.